Literature DB >> 1312638

Efficacy of oral administration of live herpes simplex virus type 1 as a vaccine.

H Irie1, Y Harada, M Kataoka, M Nagamuta, Y Moriya, M Handa, M Saito, S Matsubara, K Kojima, Y Sugawara.   

Abstract

Mice given herpes simplex virus type 1 (HSV-1) (Miyama +GC strain) intragastrically via a stainless-steel cannula were rendered immune to subsequent lethal intraperitoneal (i.p.) challenge with HSV-1. The orally administered HSV-1 was completely inactivated in the stomach within a few minutes of inoculation. However, systemic immunity was established 14 days after oral inoculation with the virus and retained for up to 6 months. The mechanisms of establishing systemic immunity were investigated by means of adoptive transfer comparisons. When splenic cells from HSV-1-immunized mice were transplanted into nonimmunized mice, all of the recipient mice survived after a lethal i.p. challenge with the virus. Immunity was not established in antithymocyte serum-treated mice or by transfer of serum from immunized to nonimmunized mice. In addition, all HSV-1-immunized mice died after lethal challenge with HSV-2 and influenza virus A. These findings suggest that the immunity was virus specific, with T lymphocytes playing a major role in its establishment. The present study therefore supports the possibility of oral immunization with live HSV-1 as a vaccine.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1312638      PMCID: PMC289038     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines.

Authors:  I M Onorato; J F Modlin; A M McBean; M L Thoms; G A Losonsky; R H Bernier
Journal:  J Infect Dis       Date:  1991-01       Impact factor: 5.226

2.  Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome.

Authors:  P A Chatis; C H Miller; L E Schrager; C S Crumpacker
Journal:  N Engl J Med       Date:  1989-02-02       Impact factor: 91.245

Review 3.  Infections with herpes simplex viruses (2).

Authors:  L Corey; P G Spear
Journal:  N Engl J Med       Date:  1986-03-20       Impact factor: 91.245

4.  Proteins specified by herpes simplex virus. V. Purification and structural proteins of the herpesvirion.

Authors:  P G Spear; B Roizman
Journal:  J Virol       Date:  1972-01       Impact factor: 5.103

5.  Immunization by selective infection with type 4 adenovirus grown in human diploid tissue cultures. I. Safety and lack of oncogenicity and tests for potency in volunteers.

Authors:  R M Chanock; W Ludwig; R J Heubner; T R Cate; L W Chu
Journal:  JAMA       Date:  1966-02-07       Impact factor: 56.272

6.  Protection of OK-432, a Streptococcus pyogenes preparation, against lethal infection of mice with herpes simplex virus.

Authors:  Y Harada; E Kurokawa; H Endo; T Kimura; M Saito; Y Sugawara; H Irie; K Ito; M Fujii; Y Shimizu
Journal:  Microbiol Immunol       Date:  1989       Impact factor: 1.955

7.  Testing the safety and effectiveness of oral administration of a live influenza vaccine.

Authors:  G I Aleksandrova; A A Smorodintsev; N M Beljaeva; B J Vasil'ev; R A Geft; V G Panteleev; M A Sejfer; A A Selivanov
Journal:  Bull World Health Organ       Date:  1970       Impact factor: 9.408

Review 8.  Mechanism of action and selectivity of acyclovir.

Authors:  G B Elion
Journal:  Am J Med       Date:  1982-07-20       Impact factor: 4.965

9.  Cell-mediated immunity against herpes simplex induction of cytotoxic T lymphocytes.

Authors:  M J Lawman; B T Rouse; R J Courtney; R D Walker
Journal:  Infect Immun       Date:  1980-01       Impact factor: 3.441

10.  Serum immunoglobulin A antibody response in swine infected with transmissible gastroenteritis virus, as determined by indirect immunoperoxidase antibody test.

Authors:  Y Kodama; M Ogata; Y Shimizu
Journal:  Am J Vet Res       Date:  1981-03       Impact factor: 1.156

View more
  3 in total

1.  Comparison of adjuvant efficacy of herpes simplex virus type 1 recombinant viruses expressing TH1 and TH2 cytokine genes.

Authors:  Yanira Osorio; Homayon Ghiasi
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

2.  Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection.

Authors:  L A Morrison; D M Knipe
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

Review 3.  Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus.

Authors:  Michael W Ferenczy
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.